Drug Profile


Alternative Names: Amodiaquine/artesunate; Artesunate 200mg/amodiaquine 270mg; Artesunate Amodiaquine Winthrop; AS/AQ; ASAQ; Coarsucam

Latest Information Update: 28 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; sanofi-aventis
  • Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
  • Class 3-ring heterocyclic compounds; Aminoquinolines; Antimalarials; Artemisinins; Diethylamines; Herbal medicines; Small molecules; Succinates
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 28 Jul 2016 No recent reports on development identified - Phase-III for Malaria (In adolescents, In children, In the elderly, In infants, In adults) in Brazil (PO)
  • 01 Jun 2013 Sanofi completes a phase III trial in Malaria (in adolescents, in adults, in children, in infants, in the elderly) in Brazil (NCT01378286)
  • 01 Jan 2012 Phase-III clinical trials in Malaria (in adolescents, in adults, in children, in infants, in the elderly) in Brazil (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top